arrow
M

Michele Maio

University of Siena
H指数:99
被引数:8.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The conformation-selective PI3Kδ inhibitor roginolisib in patients with advanced or metastatic cancer, including metastatic uveal melanoma: first-in-human clinical trial

在晚期或转移性癌症患者中具有构象选择性的PI3Kδ抑制剂roginolisib的临床试验:首次人体试验,包括转移性葡萄膜黑色素瘤

2026-10-090
OAAI
Transposable elements and homotypic niches drive immune dynamics and resistance in melanoma epigenetic-based immunotherapy

转座元件和同型微环境驱动黑色素瘤表观遗传基础免疫治疗的免疫动态和抗性

2026-08-070
OA
Circulating EV-microRNAs are dynamic biomarkers of resistance to therapeutic immunomodulation in metastatic melanoma

循环EV-miRNA是转移性黑色素瘤对治疗性免疫调节抵抗的动态生物标志物

2026-05-080
OAAI
Neoadjuvant Intralesional Targeted Immunocytokines (Daromun) in Stage III Melanoma.

新辅助病灶内靶向免疫细胞因子(Daromun)在III期黑色素瘤中的应用。

2025-07-070
PREAI
Pembrolizumab in microsatellite-instability-high and mismatch-repair-deficient advanced solid tumors: updated results of the KEYNOTE-158 trial

帕博利珠单抗在微卫星高度不稳定和错配修复缺陷型晚期实体瘤中的研究:KEYNOTE-158试验的更新结果

2025-02-200
PRE
DNA methylation status classifies pleural mesothelioma cells according to their immune profile: implication for precision epigenetic therapy

DNA甲基化状态根据其免疫表型对胸膜间皮瘤细胞进行分类:对精准表观遗传治疗的启示

2025-02-180
OA
Pembrolizumab in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) and non-MSI-H/non-dMMR advanced endometrial cancer: Phase 2 KEYNOTE-158 study results

帕博利珠单抗在微卫星高度不稳定/错配修复缺陷(MSI-H/dMMR)和非微卫星高度不稳定/非错配修复缺陷(non-MSI-H/non-dMMR)晚期子宫内膜癌中的疗效:KEYNOTE-158研究II期结果

2025-02-012
PRE
Pembrolizumab for the First-Line Treatment of Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma: Results from the Single-Arm, Open-Label, Phase III KEYNOTE-913 Study
2024-10-080
OAAI
Nivolumab plus relatlimab vs nivolumab in previously untreated metastatic or unresectable melanoma: 3-year subgroup analyses from RELATIVITY-047

Nivolumab联合relatlimab与nivolumab单药治疗既往未治疗的转移性或不可切除性黑色素瘤:RELATIVITY-047研究的3年亚组分析

2024-09-010
PRE
Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial (vol 199, 113531, 2024)
2024-05-010
PRE
Results from KEYNOTE-B99: Phase 2 study of first-line (1L) pembrolizumab (pembro) plus investigational agents and chemotherapy (chemo) for extensive-stage small-cell lung cancer (ES-SCLC)
2024-04-050
PRE